New Update: Gedatolisib in the VIKTORIA-1 Study Presented at ASCO 2026
Viktoria is not a patient, and she is not a woman I know… 😊
This is a new study that was conducted very recently (not in Israel).
The VIKTORIA-1 study is one of the most interesting studies presented this week at ASCO 2026, and the results are certainly noteworthy.
What Did the Study Evaluate?
The study evaluated the combination of:
Gedatolisib + Palbociclib + Fulvestrant
versus:
Alpelisib + Fulvestrant
Key Results
- 11.1 months progression-free survival (PFS) with the new combination
- 5.6 months progression-free survival in the comparator arm
In other words, this represents an almost doubling of progression-free survival.
This can be clearly seen in the graph, where the progression-free survival curves begin to separate significantly at an early stage of treatment.
The benefit was also observed among patients without a PIK3CA mutation, while maintaining a relatively favorable safety profile.
Why Is This Study Important?
This is exactly the type of study I like to see.
Not just a small improvement in one endpoint or another, but the opening of new treatment opportunities for patients who may not be suitable candidates for the targeted therapies that have been available until now.
The Importance of Following Clinical Trials in Real Time
At Trial-In Pharma, we follow studies like these in real time, long before they become headlines in newspapers or on social media.
Why is this important?
Because once a study becomes “news,” enrollment has often already closed, or access becomes significantly more challenging.
Who Might This Be Relevant For?
If you or a loved one is facing advanced breast cancer (Stage IV), especially when the CDK4/6 and PI3K/AKT/mTOR pathways are involved, it may be worthwhile exploring which innovative treatment options and clinical trials are currently available worldwide.
Would You Like to Explore What Options May Be Available for You?
Contact us.
Kind regards,
Nir Erez
Trial-In Pharma
Source: Hurvitz et al. VIKTORIA-1 Trial, Journal of Clinical Oncology (2026), presented at ASCO 2026. Copyright © ASCO and the study authors. All rights reserved.
Figure adapted from Hurvitz et al., VIKTORIA-1, ASCO 2026. Copyright © American Society of Clinical Oncology (ASCO). Used for educational purposes.